Despite recent attempts to take advantage of dendritic cell (DC)-based vaccines for cancer
immunotherapy, the results of clinical studies have been disappointing. This is mainly as a …

Cancer vaccines have undergone a renaissance because of recent clinical trials showing
promising immunologic data and some clinical benefit to patients. Current trials exploiting …

Dendritic cells (DCs) are the most potent APCs, with the ability to orchestrate a repertoire of
immune responses. DCs play a pivotal role in the initiation, programming and regulation of …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

The use of dendritic cells (DCs) for the generation of anti-tumour immunity has been the
focus of a vast array of scientific and clinical studies. The ability of DCs to present protein …

Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for
harnessing the potential of a patient's own immune system to eliminate tumor cells in …

The ability of immune therapies to control cancer has recently generated intense interest.
This therapeutic outcome is reliant on T cell recognition of tumour cells. The natural function …

Therapeutic cancer vaccines rely on the immune system to eliminate tumor cells. In contrast
to chemotherapy or passive (adoptive) immunotherapies with antibodies or ex vivo …

ABSTRACT B and T lymphocytes are the effectors of specific immunity. However, their
function is critically dependent on dendritic cells (DC). DC are professional antigen …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells (APCs), and
are capable of stimulating naive T cells and driving primary immune responses. Due to this …